Following hip fracture increases after a reduction in reimbursement rates for DXA scans led to fewer scans, a UAB physician joined other advocates and successfully lobbied to increase DXA scan reimbursements to better identify and reduce hip fractures.
Researchers at Mayo Clinic Center for Individualized Medicine have discovered a potential cause and a promising new treatment for inflammatory myofibroblastic tumors, a rare soft tissue cancer that does not respond to radiation or chemotherapy.
Immunotherapy continues to revolutionize the field of non–small cell lung cancer (NSCLC), with researchers now focusing on the optimal use of immune agents in the frontline setting.
The World Stem Cell Summit & RegMed Capital Conference has invited five faculty members from the Nova Southeastern University (NSU) Cell Therapy Institute to present on their research related to advancing new approaches to cancer immunotherapy and regenerative medicine at the organization’s 12th annual meeting.
Researchers from around the country who are studying alcohol’s negative effects on the body discussed their latest findings during a meeting at Loyola University Chicago’s Health Sciences campus.
Researchers at the University of Cincinnati (UC) have discovered that an ion channel, active within T cells (white blood cells), could be targeted to reduce the growth of head and neck cancers.
Therapies designed to help the body's immune system attack cancer cells are proving to be effective for some patients with advanced cases of the disease.
Photoimmunotherapy blows up tumors, spares healthy cells By Charles Jolie Nov. 14, 2016 When Kerstin Stenson, MD, describes the innovative technique she is helping develop to fight cancer, it seems like she’s describing a Tom Clancy military espionage novel. Stenson is treating patients with photoimmunotherapy, PIT for short, an experimental technique that combines the immune system’s ability to target cancer cells precisely with laser energy’s ability to destroy those cells.
Jeffrey S. Weber, MD, PhD, deputy director of NYU Langone’s Perlmutter Cancer Center, has received a 2016 “Giants of Cancer Care” Award, presented by OncLive, a professional organization for oncologists.
Virginia Tech scientists have developed a new cancer drug that uses gold nanoparticles created by the biotech firm CytImmune Sciences to deliver paclitaxel — a commonly used chemotherapy drug directly to a tumor.
The gut microbiomes of patients with antiphospholipid syndrome show higher levels of phospholipid-producing bacteria, and this findings point to microbes being a trigger for this life-threatening disease, according to new research findings presented this week at the 2016 ACR/ARHP Annual Meeting in Washington.
TSRI Researchers Believe Cell Population May Provide a New Cancer Drug Target
A study led by researchers at Beth Israel Deaconess Medical Center (BIDMC), in collaboration with scientists at Walter Reed Army Institute of Research (WRAIR), Janssen Vaccines & Prevention B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson and Gilead Sciences, Inc., has demonstrated that combining an experimental vaccine with an innate immune stimulant may help lead to viral remission in people living with HIV. In animal trials, the combination decreased levels of viral DNA in peripheral blood and lymph nodes, and improved viral suppression and delayed viral rebound following discontinuation of anti-retroviral therapy (ART). The research team’s findings appeared online today in the journal Nature.
Immunotherapy has revolutionized treatment options in oncology, neurology, and many infectious diseases and now there is fresh hope that the same method could be used to treat or even functionally cure HIV, according to two related studies from Perelman School of Medicine at the University of Pennsylvania, the University of Alabama at Birmingham (UAB), and the National Institutes of Health (NIH).
A Ludwig Cancer Research study shows that an experimental drug currently in clinical trials can reverse the effects of troublesome cells that prevent the body’s immune system from attacking tumors.
Baylor Scott & White Research Institute will be home to one of four new Centers of Research Translation, or CORTs. National Institute of Arthritis and Musculoskeletal and Skin Diseases will fund $8.5 million over five years toward the center’s research, which aims to better understand the development of severe lupus in children and could ultimately lead to new personalized treatments.
University of California, Irvine and MIT researchers have developed a new strategy to immunize against microbes that invade the gastrointestinal tract, including Salmonella, which causes more foodborne illness in the United States than any other bacteria.
Many cancer patients respond favorably to immunotherapies, but most do not. Blame for treatment failures is usually attributed to so-called “cold” tumors, thought to lack key targets able to provoke an immune response. Two studies in the Nov. 7 issue of PNAS shift the focus to other factors.
The team evaluated 15 randomized controlled trials published between 2011 and 2015, assessing the benefits and harms of targeted or immune checkpoint inhibitors in 6,662 patients with cancer that had spread to the lymph nodes and surgery was not an option, or distant metastatic melanoma.
The Ottawa Hospital, the Children’s Hospital of Eastern Ontario (CHEO), the University of Ottawa (uOttawa) and McMaster University congratulate Turnstone Biologics Inc. (Turnstone) on securing $41.4 million U.S. in new private investments.
Researchers at the University of Virginia School of Medicine have developed an experimental vaccine to battle melanoma, a deadly form of skin cancer. It’s an example of cutting-edge immunotherapy, the harnessing of the immune system’s power to battle disease. But it also represents a fulfillment of potential UVA recognized 25 years ago. In 1991, with financial support from businessman Beirne B.
The cornerstone of genetics is the loss-of-function experiment. In short, this means that to figure out what exactly gene X is doing in a tissue of interest—be it developing brain cells or a pancreatic tumor—you somehow cut out, switch off or otherwise destroy gene X in that tissue and then watch what happens. That genetic litmus test has been applied since before people even knew the chemical DNA is what makes up genes. What has changed radically are the tools used by biologists to inactivate a gene.
Researchers in Japan have discovered that the adrenergic nervous system controls when white blood cells circulate through the body, boosting the immune response by retaining T and B cells in lymph nodes at the time of day when they are most likely to encounter foreign antigens. The study, “Adrenergic control of the adaptive immune response by diurnal lymphocyte recirculation through lymph nodes,” will be published online October 31 ahead of issue in The Journal of Experimental Medicine.
The recent approval of pembrolizumab (Keytruda) in recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) following progression on a platinum-based chemotherapy was a significant advancement for the disease. However, Barbara A. Burtness, MD, said, the approval of the PD-1 inhibitor only scratches the surface of the potential of immunotherapies in head and neck cancer.
A recent Cochrane Review has found evidence from randomised trials, that taking an oral vitamin D supplement in addition to standard asthma medication is likely to reduce severe asthma attacks.
SLU researchers report new findings about how the immune system directs T cells to learn tolerance for the body's own cells.
An innovative, new, patient-driven natural history registry for the rare and poorly understood immune system disorder Castleman disease (CD) will propel care and research for CD through a collaborative research agreement between Janssen Research & Development, LLC; the Castleman Disease Collaborative Network (CDCN); and the University of Pennsylvania.
A new method to determine how effectively immune cells kill their targets could help personalize immune therapies.
Asthma caused by adult exposure to cockroach detritus is blocked in mice that were vaccinated as newborns with a particular bacteria, Enterobacter that expresses alpha-1,3-glucan molecules on its surface.
The Latest in Cell Biology News
Spurred by NYS Trade Mission to Cuba in 2015, Buffalo cancer center will conduct a clinical trial with CIMAvax-EGF, groundbreaking immunotherapy for lung cancer developed in Cuba — becoming the first American center to receive FDA authorization to sponsor a clinical trial offering a Cuban-made therapy to U.S. patients — and will work to speed this and other innovative therapies to patients worldwide through a historic new business venture with Cuban research institute
SASKATOON - University of Saskatchewan (U of S) scientists have developed a new immunotherapy technique that nearly eliminates the allergic response to peanut and egg white proteins in food-allergic mice, reducing the anaphylactic response by up to 90 per cent with only one treatment.
Pembrolizumab, an immunotherapy drug that was extensively evaluated by UCLA cancer researcher Dr. Edward Garon, has been approved by the U.S. Food & Drug Administration as first-line treatment for non-small cell lung cancer (NSCLC). The first-line designation means that some patients will have access to the drug without first having to receive other treatments such as chemotherapy.
With the goal of advancing a powerful cancer treatment strategy that uses immune cells to fight the disease, benefactors Ellen and Gary Davis have generously made a $2 million gift to Weill Cornell Medicine to drive ongoing research in immunotherapy, the institution announced today.
José R. Conejo-Garcia, M.D., Ph.D. has joined Moffitt Cancer Center as co-leader of the Immunology Program and chair of the Department of Immunology.
Scientists at the University of Basel discovered a fundamental new mechanism explaining the inadequate immune defense against chronic viral infection. These results may open up new avenues for vaccine development. They have been published in the journal “Science Immunology”.
Researchers at University of California San Diego School of Medicine have discovered that Zika virus infection leads to modifications of both viral and human genetic material. These modifications — chemical tags known as methyl groups — influence viral replication and the human immune response.
Researchers, led by Steven Almo, Ph.D., and Chandan Guha, M.B.B.S., Ph.D., at Albert Einstein College of Medicine have received a five-year, $2.6 million NIH grant to make immunotherapy agents that are more precise and effective at treating various types of cancers.
A team of investigators at Children’s Hospital Los Angeles has received a major, three-year grant from the V Foundation for Cancer Research to study the effects of chemoimmunotherapy in children with neuroblastoma.
Currently, human papillomavirus (HPV) vaccination rates remain low across the U.S., with fewer than 40% of girls and just over 21% of boys receiving the recommended vaccine series. Research from Roswell Park Cancer Institute has identified barriers that need to be overcome to improve vaccination rates, as well as possible strategies for doing so. The study has been published online ahead of print in the Journal of Cancer Education.
In a phase I clinical trial, patients with previously treated advanced non-small cell lung cancer (NSCLC) have showed initial response and disease control from the drug combination of ramucirumab and pembrolizumab. Roy S. Herbst, MD, PhD, Chief of Medical Oncology at Yale Cancer Center and Smilow Cancer Hospital at Yale New Haven, will present the interim data of the clinical trial at the European Society for Medical Oncology (ESMO) Congress today.
Though first documented 70 years ago, the Zika virus was poorly understood when it burst onto the scene in the Americas in 2015. In one of the first and largest studies of its kind, a research team lead by virologists at Beth Israel Deaconess Medical Center (BIDMC) has characterized the progression of two strains of the viral infection. The study, published online this week in Nature Medicine, revealed Zika’s rapid infection of the brain and nervous tissues, and provided evidence of risk for person-to-person transmission.
The Association of American Cancer Institutes will present the AACI Distinguished Scientist Award to James P. Allison, PhD, on October 24, during the 2016 AACI/CCAF Annual Meeting, in Chicago.
The FDA approval of Tecentriq ushered in the first new treatment for advanced bladder cancer in 30 years.
The UCSF Helen Diller Family Comprehensive Cancer Center is one of only 12 academic centers in the U.S. joining a large national precision medicine study that aims to improve survival for pancreatic cancer patients. The trial, called Precision Promise, is a joint effort between the Pancreatic Cancer Action Network, cancer research and treatment centers, and the pharmaceutical industry. The goal of Precision Promise is to double survival by 2020.
There has been much recent excitement about immunotherapy and the use of genetically engineered chimeric antigen receptor (CAR) T cells. Historically, CAR T cell immunotherapy has aimed to boost the immune system by giving immune cells the information they need to better recognize tumor cells as foreign and attack them. New work led by Hans-Guido Wendel, MD, of Memorial Sloan Kettering Cancer Center, and collaborator Karin Tarte of the University of Rennes, France, illustrates an untapped potential of CAR T cells to act as targeted delivery vehicles that can function as “micro-pharmacies” for precise therapeutic delivery. Reported by an international team of researchers and set to publish online in Cell on September 29, this work both defines a critical lesion that leads to lymphoma development and identifies a potential new treatment modality.
A leading authority on developing innovative immunotherapy treatments is Rush' new division chief of the Hematology, Oncology and Cell Therapy. Dr. Dr. Timothy Kuzel, a leading expert on cancer immunotherapies, will focus on continuing to assemble multidisciplinary teams to craft individualized treatments for each patient.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right